Regulatory PathRegulatory requirements compared

Active substances

Cetirizine + Pseudoephedrine

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
CIRRUS 5-120MG PROLONG RELEASE F-C TABS.120,5 mg,mgProlonged-release tablet · Oral use14 BlisterSAR 19.90NCE · OTCGlaxo Saudi Arabia LtdWithdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
ZYRTEC-D 12 HOUR5MG;120MGtablet, extended release · oralKENVUE BRANDSOver-the-counter10 Aug 2001
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE5MG;120MGtablet, extended release · oralIVAX SUB TEVA PHARMSOver-the-counter25 Feb 2008
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE5MG;120MGtablet, extended release · oralPLD ACQUISITIONSOver-the-counter5 Mar 2008
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE5MG;120MGtablet, extended release · oralSUN PHARM INDS LTDOver-the-counter28 Sep 2012
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE5MG;120MGtablet, extended release · oralPPI-DACOver-the-counter16 Nov 2018
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE5MG;120MGtablet, extended release · oralAUROBINDO PHARMA LTDDiscontinued8 Mar 2023
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE5MG;120MGtablet, extended release · oralUNICHEMDiscontinued10 Sep 2024

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
REACTINE COMPLETE022461625 MG; 120 MGTABLET (EXTENDED-RELEASE) · ORALKENVUE CANADA INC.

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACCETIRIZINE-PSE ER 5-120 MG TAB$0.56251per EA23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.